Summary & Overview
HCPCS Q4283: Biovance Tri-Layer Biologic Wound Matrix, Per sq cm
HCPCS Level II code Q4283 identifies Biovance tri-layer (Biovance 3L) billed per square centimeter as an add-on product used in advanced wound care. As an add-on code, Q4283 is reported in addition to a primary wound management procedure when a clinician applies a tri-layer biologic wound matrix to promote tissue repair. Nationally, add-on product codes like Q4283 matter because they affect how wound-care interventions are documented and how payers evaluate bundled services and supplemental product payments.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical role of Biovance tri-layer in wound healing, guidance on typical sites of service where this product is used, and a summary of payer coverage considerations and common modifier interactions. The publication also outlines benchmarking areas and policy topics relevant to add-on biologic products, including documentation expectations and billing practices when reporting an add-on per-square-centimeter code alongside a primary procedure. Data not available in the input will be identified where applicable.
Billing Code Overview
HCPCS Level II code Q4283 describes Biovance tri-layer or Biovance 3L, billed per square centimeter as an add-on, list separately in addition to the primary procedure. This code represents a multi-layer biologic wound matrix product intended for application to wounds requiring advanced tissue support and healing.
-
Service type: Advanced wound care product application (biologic wound matrix)
-
Typical site of service: Outpatient wound care clinics, hospital outpatient departments, ambulatory surgery centers, and other settings where a primary procedure for wound management is performed
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic, non-healing full-thickness or partial-thickness wound (for example, a lower-extremity diabetic foot ulcer or a chronic venous stasis ulcer) that has failed conservative wound care such as debridement, offloading, compression, and advanced dressings over several weeks. The procedure involves application of a commercially prepared, tri-layer amniotic membrane product, billed as Q4283 per square centimeter as an add-on supply in addition to the primary wound procedure. Clinical workflow: wound assessment and measurement, appropriate debridement (sharp or enzymatic) to remove nonviable tissue, hemostasis, wound bed preparation, selection and sizing of the Q4283 product to cover the defect, placement and securement of the graft/matrix, application of appropriate secondary dressings, and patient/caregiver wound care instructions. Typical sites of service include outpatient wound care centers, hospital outpatient departments, ambulatory surgical centers, and physician office settings where advanced biologic grafting is performed. Usual clinical monitoring includes periodic dressing changes and serial wound measurements to document uptake and progression toward closure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |